S8010

(±)-スルピリド

Name: (±)-スルピリド
Brand: SIGMA

D2 dopamine antagonist, powder

別名:

(±)-5-(アミノスルホニル)-N-[(1-エチル-2-ピロリジニル)メチル]-2-メトキシベンズアミド, (±)-N-1-(エチルピロリジン-2-イルメチル)-2-メトキシ-5-スルファモイルベンズアミド

ログインで組織・契約価格をご覧ください。

サイズを選択してください

この商品について

実験式（ヒル表記法）:

C₁₅H₂₃N₃O₄S

CAS番号:

15676-16-1

分子量:

341.43

NACRES:

NA.77

PubChem Substance ID:

24277933

UNSPSC Code:

12352200

EC Number:

239-753-7

MDL number:

MFCD00055061

主要文書

すべての文書を表示

テクニカルサービス

お困りのことがあれば、経験豊富なテクニカルサービスチームがお客様をサポートします。

お手伝いします

テクニカルサービス

お困りのことがあれば、経験豊富なテクニカルサービスチームがお客様をサポートします。

お手伝いします

製品名

(±)-スルピリド,

InChI key

BGRJTUBHPOOWDU-UHFFFAOYSA-N

InChI

1S/C15H23N3O4S/c1-3-18-8-4-5-11(18)10-17-15(19)13-9-12(23(16,20)21)6-7-14(13)22-2/h6-7,9,11H,3-5,8,10H2,1-2H3,(H,17,19)(H2,16,20,21)

SMILES string

CCN1CCCC1CNC(=O)c2cc(ccc2OC)S(N)(=O)=O

form

powder

color

white

solubility

45% (w/v) aq 2-hydroxypropyl-β-cyclodextrin: 8.0 mg/mL, 0.1 M HCl: soluble, H₂O: slightly soluble, ethanol: soluble

originator

Sanofi Aventis

storage temp.

2-8°C

Quality Level

100

Gene Information

human ... CA1(759), CA2(760), CA4(762), CA5A(763), CA5B(11238), CA9(768), DRD2(1813)

Application

(±)-Sulpiride was used to study the effect of dopamine D₂ receptor signaling on calcium channels in rat pituitary melanotropic cells.⁴⁷

Biochem/physiol Actions

(±)-Sulpiride is a D₂ dopamine antagonist and an effective treatment for schizophrenia when used in combination with clozapine, a relatively weak D₂-dopaminergic antagonist. It is an antipsychotic agent and also exhibits neuroleptic properties but poorly penetrates the central nervous system.^45,46

Features and Benefits

This compound was developed by Sanofi Aventis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Preparation Note

溶液は、4°Cで数日間は保存することができます。

pictograms

GHS08

signalword

Warning

hcodes

H361

pcodes

P201 - P202 - P280 - P308 + P313 - P405 - P501

Hazard Classifications

Repr. 2

保管分類

11 - Combustible Solids

wgk

WGK 2

flash_point_f

Not applicable

flash_point_c

Not applicable

適用法令

試験研究用途を考慮した関連法令を主に挙げております。化学物質以外については、一部の情報のみ提供しています。製品を安全かつ合法的に使用することは、使用者の義務です。最新情報により修正される場合があります。WEBの反映には時間を要することがあるため、適宜SDSをご参照ください。

S8010-BULK: + S8010-100G: + S8010-250G: + S8010-25G: + S8010-VAR:

jan

最新バージョンのいずれかを選択してください：

試験成績書（COA）

Lot/Batch Number

適切なバージョンが見つかりませんか。

特定のバージョンが必要な場合は、ロット番号またはバッチ番号で特定の証明書を検索できます。

COAを検索

以前この製品を購入いただいたことがある場合

文書ライブラリで、最近購入した製品の文書を検索できます。

文書ライブラリにアクセスする

Dopamine D2 receptor stimulation differentially affects voltage-activated calcium channels in rat pituitary melanotropic cells.

J A Keja et al.

The Journal of physiology, 450, 409-435 (1992-05-01)

1. Whole-cell voltage clamp recordings were made from 141 rat pituitary melanotropic cells in short-term, serum-free, primary culture. The effects of the dopamine D2 receptor agonist, LY 171555, on sodium, potassium and barium currents were investigated. 2. Application of 1

Sulpiride augmentation in people with schizophrenia partially responsive to clozapine. A double-blind, placebo-controlled study.

R Shiloh et al.

The British journal of psychiatry : the journal of mental science, 171, 569-573 (1998-03-31)

We hypothesised that a combined regimen of clozapine, a relatively weak D2-dopaminergic antagonist, and sulpiride, a selective D2 blocker, would demonstrate a greater antipsychotic efficacy by enhancing the D2 blockade of clozapine. Twenty-eight people with schizophrenia, previously unresponsive to typical

Identifying clinically meaningful symptom response cut-off values on the SANS in predominant negative symptoms.

Stephen Z Levine et al.

Schizophrenia research, 145(1-3), 125-127 (2013-02-12)

The treatment and measurement of negative symptoms are currently at issue in schizophrenia, but the clinical meaning of symptom severity and change is unclear. To offer a clinically meaningful interpretation of severity and change scores on the Scale for the

Carbonic anhydrase inhibitors: Hypoxia-activatable sulfonamides incorporating disulfide bonds that target the tumor-associated isoform IX.

Giuseppina De Simone et al.

Journal of medicinal chemistry, 49(18), 5544-5551 (2006-09-01)

An approach for designing bioreductive, hypoxia-activatable carbonic anhydrase (CA, EC 4.2.1.1) inhibitors targeting the tumor-associated isoforms is reported. Sulfonamides incorporating 3,3'-dithiodipropionamide/2,2'-dithiodibenzamido moieties were prepared and reduced enzymatically/chemically in conditions present in hypoxic tumors, leading to thiols. The X-ray crystal structure

Expanding Role of Dopaminergic Inhibition in Hypercapnic Responses of Cultured Rat Carotid Body Cells: Involvement of Type II Glial Cells.

Erin M Leonard et al.

International journal of molecular sciences, 21(15) (2020-08-06)

Dopamine (DA) is a well-studied neurochemical in the mammalian carotid body (CB), a chemosensory organ involved in O2 and CO2/H+ homeostasis. DA released from receptor (type I) cells during chemostimulation is predominantly inhibitory, acting via pre- and post-synaptic dopamine D2

(±)-スルピリド

D2 dopamine antagonist, powder

サイズを選択してください

この商品について

主要文書

特性

製品名

InChI key

InChI

SMILES string

form

color

solubility

originator

storage temp.

Quality Level

Gene Information

関連するカテゴリー

詳細

Application

Biochem/physiol Actions

Features and Benefits

Preparation Note

安全性情報

pictograms

signalword

hcodes

pcodes

Hazard Classifications

保管分類

wgk

flash_point_f

flash_point_c

適用法令

S8010-BULK: + S8010-100G: + S8010-250G: + S8010-25G: + S8010-VAR:

資料

試験成績書（COA）

以前この製品を購入いただいたことがある場合

参考文献

テクニカルサービス